MedTrace Logo

Paricalcitol Improves Anemia of Inflammation

NCT02876211 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-12-09

No results posted yet for this study

Summary

Anemia of inflammation (AI) is a common comorbidity in hemodialysis patients. Paricalcitol is a selective vitamin D receptor activator with potential benefits on anti-inflammatory cytokines expression. The paricalcitol for the secondary hyperparathyroidism control may improve AI decreasing erythropoietin stimulating agents (ESAs) dosage.

Conditions

Interventions

DRUG

Paricalcitol

Paricalcitol 2 capsules/three times per week

DRUG

Epoetin beta

epoetin 1-3 times per week

DRUG

Placebo

Placebo 2 capsules/three times per week

Sponsors & Collaborators

  • Hospital Son Espases

    lead OTHER

Principal Investigators

  • Miguel Uriol, Ph.D.M.D. · Son Espases University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2022-08-31
Completion
2024-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02876211 on ClinicalTrials.gov